Previously, we demonstrated that the Src tyrosine kinase interacts with the Shp-2 tyrosine phosphatase. To determine whether Shp-2 regulates Src kinase activity, we measured Src activity in cells overexpressing wildtype or catalytically-inactive C463S Shp-2. We observed a 2 ± 3-fold increase in the speci®c activity of Src in both cell types and the increase did not appear to be due to dephosphorylation of Tyr 527 or phosphorylation of Tyr 416 on Src. Conversely, we observed a 2 ± 3-fold decrease in the speci®c activity of Src when Shp-2 expression was inhibited. Using glutathione S-transferase-fusion proteins, we demonstrated that Shp-2 binds to the SH3 domain of Src. Our ®ndings reveal that the Shp-2 tyrosine phosphatase can regulate the Src tyrosine kinase by a non-enzymatic mechanism. We also found that the phosphatase activity of Shp-2 immunoprecipitates is downregulated in cells transformed by Src or other proteins, and that Shp-2 preferentially associates with the membrane fraction of transformed cells. We suggest that membrane-association of Shp-2 is important for regulating Shp-2 activity.
Introduction
Activity of the c-Src (Src) tyrosine kinase is normally repressed, and loss of that repression results in uncontrolled cell growth and malignant transformation (reviewed in Brown and Cooper, 1996) . Thus, it is important to search for cellular mechanisms that regulate Src activity. Both tyrosine kinases and phosphatases are known to do so (reviewed in Brown and Cooper, 1996; Tonks and Neel, 1996) . For example, signaling through the platelet-derived growth factor (PDGF) receptor tyrosine kinase activates Src (Kypta et al., 1987) , and activated Src is required for G 1 /S transition (Twamley-Stein et al., 1993; Roche et al., 1995) . The nonreceptor, C-terminal Src kinase (CSK; Okada and Nakagawa, 1989; Nada et al., 1991) suppresses Src activity by phosphorylating Src on Tyr 527 (Kmiecik and Shalloway, 1987; Piwnica-Worms et al., 1987; Cartwright et al., 1987; Reynolds et al., 1987) . Conversely, the receptor tyrosine phosphatase a and the nonreceptor tyrosine phosphatase Shp-1 activate Src by dephosphorylating Tyr 527 (Zheng et al., 1992; den Hertog et al., 1993; Somani et al., 1997) . Thus, Src activity is regulated by both receptor and nonreceptor tyrosine kinases and phosphatases.
Previously, we demonstrated that Src interacts with Shp-2 (also known as PTP1D, PTP2C, SHPTP-2, SHPTP-3 and Syp; Peng and Cartwright, 1995) , a Src homology 2 (SH2) domain-containing cytoplasmic tyrosine phosphatase that signals downstream of many tyrosine kinases and cytokine receptors (reviewed in Tonks and Neel, 1996) . Our in vitro studies showed that Shp-2 can dephosphorylate Src at Tyr 527 (Peng and Cartwright, 1995) . Shp-2 also interacts with the nonreceptor JAK and p210bcr-abl tyrosine kinases and dephosphorylates p210bcr-abl in vitro (Tauchi et al., 1994; Yin et al., 1997) . However, studies have not been done to determine whether Shp-2 regulates the activities of these non-receptor tyrosine kinases in vivo. Moreover, little is known about mechanisms that regulate tyrosine phosphatase activity.
Following PDGF or epidermal growth factor (EGF) stimulation, the tyrosine-phosphorylated growth factor receptors bind to the N-terminal SH2 domains of Shp-2 Lechleider et al., 1993a,b; Kazlauskas et al., 1993; Vogel et al., 1993) . Shp-2, in turn, binds to the SH2 domain (after PDGF stimulation) or the Src homology 3 (SH3) domain (after EGF stimulation) of Grb2-Sos and this leads to Ras activation Li et al., 1994; Wong and Johnson, 1996) . Thus, in addition to functioning as a phosphatase, Shp-2 also functions as an adaptor protein, linking growth factor receptor tyrosine kinase and Ras signaling pathways.
The purpose of this study was to determine whether Src and Shp-2 regulate each other's activity in vivo and, if so, by what mechanism. We found that Shp-2 activates Src, but not, that we can detect, by dephosphorylating Tyr 527 on Src. We also found that the phosphatase activity of Shp-2 immunoprecipitates is downregulated in cells transformed by Src or other proteins, and that Shp-2 preferentially associates with the membrane fraction of transformed cells.
Results

Shp-2 activates Src without detectably dephosphorylating Tyr 527
Previously, we and others showed that dephosphorylation of Tyr 527 on Src enhances Src tyrosine kinase activity (Cartwright et al., 1987; Kmiecik and Shalloway, 1987; Piwnica-Worms et al., 1987; Reynolds et al., 1987) . Recently, we demonstrated an interaction between Src and the Shp-2 tyrosine phosphatase (Peng and Cartwright, 1995) . To test the hypothesis that Shp-2 might activate Src by dephosphorylating Tyr 527, we needed a catalytically-inactive Shp-2 mutant as a control. Others have shown that this highly conserved cysteine in the catalytic domain of tyrosine phosphatases is required for enzymatic activity (Streuli et al., 1988 (Streuli et al., , 1990 Guan and Dixon, 1990; Guan et al., 1991; Milarski and Saltiel, 1994) . Thus, we introduced a point mutation in Shp-2, substituting serine for cysteine at residue 463 (C463S Shp-2). We sequenced the entire coding region of the mutant and veri®ed that the desired mutation was present and that no other mutations had been introduced. To con®rm that the mutant was catalytically inactive, we measured Shp-2 phosphatase activity in cells transiently overexpressing wild-type or mutant Shp-2. Because endogenous levels of Shp-2 activity are low and dicult to measure in NIH3T3 cells, we used NIH3T3 cells that were stably overexpressing the PDGF receptor for the transient expression assays, and treated the cells with PDGF to stimulate Shp-2 activity (Vogel et al., 1993) . We observed that the activity of wild-type, but not mutant Shp-2 was stimulated above endogenous levels following PDGF treatment (data not shown). Thus, we con®rmed the ®ndings of others, that the C463S Shp-2 mutant is catalytically inactive.
To determine whether Shp-2 regulates Src kinase activity, we transiently expressed wild-type or mutant C463S Shp-2 in NIH3T3 cells that were stably overexpressing chicken c-Src, and measured Src kinase activity. Immunoblotting analysis showed that Shp-2 protein levels were higher in cells overexpressing wildtype ( Figure 1a , lane 2) or mutant (lane 3) Shp-2 than in cells expressing the vector alone (lane 1). Src protein kinase activity was also higher in cells overexpressing wild-type (lane 5) or mutant (lane 6) Shp-2 than in vector-transfected cells (lane 4). Immunoblotting studies showed equivalent amounts of Src protein in all three cell lysates (lanes 7 ± 9). Thus, the speci®c activity of Src was elevated in the Shp-2 overexpressor cells. Quantitation of data revealed that Shp-2 protein levels were, on average, 2 ± 3-fold higher in cells overexpressing wild-type or mutant Shp-2 than in cells expressing the vector alone (data not shown). Similarly, the speci®c activity of Src was increased 2 ± 3-fold in the Shp-2 overexpressor cells (Figure 1b) . Furthermore, the Src activation observed in Shp-2 overexpressor cells was not due to direct dephosphorylation of Tyr 527 by Shp-2 because the Shp-2 mutant that lacked phosphatase activity was also able to activate Src.
To determine whether overexpression of Shp-2 indirectly leads to dephosphorylation of Tyr 527, we ®rst analysed tyrosine phosphorylation on Src in the Shp-2 overexpressor cells by immunoblotting with antiphosphotyrosine antibody (Figure 2a ). We observed that tyrosine phosphorylation on Src in cells expressing wild-type (lane 2) or mutant (lane 3) Shp-2 was similar to that on Src in cells expressing the vector alone (lane 1). (Equivalent amounts of Src protein were present in all lysates as shown in Figure 1a , lanes 7 ± 9). Similarly, tyrosine phosphorylation on immunoprecipitated Src was equivalent in all cases (lanes 4 ± 6). Immunoblot analysis showed equivalent levels of immunoprecipitated Src in each lane (lanes 7 ± 9). Together, the data show that overall levels of tyrosine phosphorylation on Src are not altered in Shp-2 overexpression cells.
Because overexpression of Shp-2 could indirectly lead both to dephosphorylation of Tyr 527 and to phosphorylation of Tyr 416, resulting in no net change in tyrosine phosphorylation as detected by immunoblotting with an anti-phosphotyrosine antibody, we further analysed tyrosine phosphorylation on Src in Shp-2 overexpressor cells by cyanogen-bromide mapping (Figure 2b) . In contrast to normal c-Src, which is phosphorylated in vivo on Tyr 527, mutant Y527F cSrc (which contains a phenylalanine substitution for tyrosine at residue 527) is phosphorylated in vivo on Tyr 416 (Cartwright et al., 1987) . Thus, we used the mutant Y527F c-Src as a control for Tyr 416 phosphorylation. We metabolically-labeled cells with 4 and 7) , pcDNA3-Shp-2 (lanes 2, 5 and 8) or pcDNA3-C463S Shp-2 (lanes 3, 6 and 9), and lysed 48 h later in RIPA buer. Lysates containing 20 mg of total cellular protein was resolved by SDS ± PAGE, transferred to nitrocellulose and subjected to immunoblot analysis with antiShp-2 (lanes 1 ± 3) or anti-Src (lanes 7 ± 9). Proteins were detected by ECL. Src immunoprecipitates of lysate containing 200 mg of the total cellular protein were incubated with [g-32 P]ATP and MnCl 2 for 10 min at 308C in an in vitro protein kinase assay (lanes 4 ± 6).
32 P-labeled proteins were resolved by SDS ± PAGE and visualized by autoradiography. Data are representative of six independent experiments. (b) Quantitation of data on the speci®c activity of Src from Shp-2 overexpressor cells.
32
P incorporation into Src was quanti®ed by scanning densitometry of autoradiograms. The data represent average values from six independent experiments for pcDNA3 or pcDNA3-Shp-2 transfectants, and three independent experiments for pcDNA3-C463S Shp-2 transfectants. Values are expressed relative to those for Src from pcDNA3 transfectants. Brackets indicate standard errors terminal sites of serine phosphorylation, the &10 kDa fragment (asterisk) contains the Tyr 416 site of autophosphorylation, and the &4 kDa fragment (arrowhead) contains the Tyr 527 inhibitory site of phosphorylation (Jove et al., 1987; Somani et al., 1997) . We observed slightly more Tyr 527 phosphorylation on Src from cells overexpressing wild-type (lane 2) or mutant (lane 3) Shp-2, than on Src from cells expressing the vector alone (lane 1). This slight dierence was not reproducible; additional experiments showed that Src from wild-type mutant and vector-transfected cells had similar levels of Tyr 527 phosphorylation. As predicted, Y527F c-Src was tyrosine phosphorylated at residue 416 (lane 4). We detected no Tyr 416 phosphorylation on Src from the Shp-2 overexpressor cells (lanes 2 and 3) . Together, the data show that dephosphorylation of Tyr 527 and/or phosphorylation of Tyr 416 do not appear to be the mechanisms by which Src is activated in Shp-2 overexpressor cells.
The speci®c activity of Src decreases when Shp-2 expression decreases
In a complementary approach to overexpressing Shp-2, we performed the converse experiment, in which we inhibited Shp-2 expression and examined the eect on Src kinase activity. To do so, we incubated c-Srcoverexpressor cells with sense or antisense S-oligonucleotides directed against shp-2 mRNA and measured both Shp-2 expression (by immunoblotting with a Shp-2 antibody) and Src activity (in an immune-complex in vitro kinase assay) (Figure 3 ). We observed that incubation with the shp-2 antisense oligonucleotide resulted in almost complete inhibition of Shp-2 expression (compare lanes 1 and 2), and a 2 ± 3-fold decrease in Src activity (compare lanes 3 and 4). Immunoblot analysis showed equivalent amounts of Src protein present in lanes 3 and 4 (data not shown). Thus, the speci®c activity of Src decreased when Shp-2 expression decreased. In summary, we demonstrated by two complementary, but dierent, experimental approaches, that changes in Shp-2 protein expression are associated with changes in Src kinase activity. 4 and 7) , pcDNA3-Shp-2 (lanes 2, 5 and 8) or pcDNA3-C463S Shp-2 (lanes 3, 6 and 9), and lysed 48 h later in RIPA buer containing sodium vanadate. Lysates containing 20 mg of total cellular protein (lanes 1 ± 3), or Src immunoprecipitates of lysates containing 500 mg of total cellular protein (lanes 4 ± 6) were subjected to immunoblot analysis with anti-phosphotyrosine. The ®lter was stripped of anti-phosphotyrosine antibody and rehybridized with Src antibody. Lanes 7 ± 9: lanes 4 ± 6 of the original anti-phosphotyrosine blot that were rehybridized with Src antibody. Proteins were detected by ECL. 32 P-labeled proteins were immunoprecipitated from cell lysates with anti-Src and resolved by SDS ± PAGE (upper panel).
P-labeled Src bands were excised from the gel, hydrolyzed with CNBr and the cleaved fragments were separated by electrophoresis through a 24% low-bis gel (lower panel) and detected by autoradiography with an intensifying screen at 7808C. Left margin: protein sizes are indicated in kilodaltons. Right margin: arrow, the &31 kDa fragment of Src containing the N-terminal sites of serine phosphorylation; asterisk, the &10 kDa fragment of Src containing the Tyr 416 site of phosphorylation; arrowhead, the &4 kDa fragment of Src containing the Tyr 527 site of phosphorylation. Data are representative of three independent experiments Figure 3 Eect of inhibiting Shp-2 expression on Src kinase activity. 3T3/c-Src cells were incubated for 40 h with 2 mM of sense (S; lanes 1 and 3) or antisense (AS; lanes 2 and 4) Soligonucleotides directed against shp-2 mRNA. Cells were lysed in RIPA buer, and lysate containing 14 mg of total cellular protein was subjected to immunoblot analysis with anti-Shp-2 (lanes 1 and 2). A non-speci®c immunoreactive band running below Shp-2 was present in both lanes. Src immunoprecipitates of lysate containing 40 mg of total cellular protein were subjected to an in vitro protein kinase assay, as in the legend to The SH3 domain of Src binds Shp-2 Protein binding to speci®c domains in Src family kinases can activate the kinases by stabilizing them in an open, active, conformational state (reviewed in Brown and Cooper, 1996) . To determine whether Shp-2 might activate Src by this mechanism, we identi®ed the Shp-2 binding site on Src. To do so, we expressed various Src domains as bacterial fusion proteins to GST (glutathione S-transferase), incubated the fusion proteins with lysates of NIH3T3 cells overexpressing Shp-2, and assayed for Shp-2 binding to the Src fusion proteins by immunoblot analysis with anti-Shp-2 ( Figure 4 , upper left panel). We observed that all GST-Src fusion proteins that contained the Src SH3 domain bound Shp-2 (lanes 5 ± 8), whereas fusions that lacked the SH3 domain (lanes 3 and 4), and GST alone (lane 2), did not. Thus, the SH3 domain of Src appeared to bind Shp-2. To con®rm this, we expressed a Src mutant lacking the SH3 domain (DSH3) as a GST fusion protein and tested it for binding to Shp-2 (upper right panel). The DSH3 Src mutant did not bind Shp-2 (lane 11), whereas a truncated Src that contained the SH3 domain (lane 10) did bind Shp-2. Thus, the SH3 domain of Src binds to Shp-2 in vitro. The results are summarized schematically in the lower panel.
The phosphatase activity of Shp-2 immunoprecipitates is downregulated in NIH3T3 cells transformed by Src or other proteins
To determine whether Src regulates Shp-2 phosphatase activity, we measured Shp-2 activity in NIH3T3 cells that were stably overexpressing Src proteins that had a broad range in speci®c activity and transforming ability: normal c-Src (with low levels of activity), partially activated and transforming Y527F c-Src, or fully activated and transforming v-Src (Figure 5a ). We immunoprecipitated Shp-2 from cell lysates and measured its ability to dephosphorylate 32 P-labeled myelin basic protein. We observed that the phosphatase activity of Shp-2 immunoprecipitates from c-Src overexpressor cells was similar to that from NIH3T3 cells. In contrast, the phosphatase activity of Shp-2 immunoprecipitates from Y527F c-Src or v-Src overexpressor cells was 50 or 70% less, respectively, than that from NIH3T3 cells. Immunoblot analysis showed that Shp-2 protein levels were equivalent in all cell lines (data not shown). Thus, the phosphatase activity of Shp-2 immunoprecipitates was not altered in cells overexpressing normal c-Src, but was decreased in cells overexpressing Y527F c-Src or v-Src. Several dierent mechanisms could explain the decreased Shp-2 activity observed in cells overexpressing Y527F c-Src or v-Src:
(1) activation of Src results in decreased Shp-2 activity; and/or (2) events in transformed cells other than activation of Src results in decreased Shp-2 activity.
To determine whether Shp-2 activity is downregulated in cells transformed by proteins other than Src, we measured Shp-2 activity in Shp-2 immunoprecipitates from lysates of NIH3T3 cells transformed by polyoma middle T antigen (mT; Cartwright et al., Figure 4 In vitro binding of Shp-2 to the SH3 domain of Src. NIH3T3 cells were transfected with pcDNA3-Shp-2 and lysed 48 h later in NP-40 buer. Lysate containing 200 mg of total cellular protein was incubated for 4 h at 48C with approximately 0.5 mM of GST alone (lanes 2 and 9) or GST-Src fusion protein (lanes 3 ± 8, 10 and 11) which had been immobilized on glutathione sepharose beads. Proteins bound to GST or GSTSrc fusions were detected by immunoblot analysis with anti-Shp-2 (lanes 2 ± 11). Lanes 1 and 12: Lysate containing 20 mg of total cellular protein was loaded directly on the gel prior to transfer and immunoblotting with anti-Shp-2. Data are representative of three independent experiments. A schematic representation of Shp-2 binding to various Src proteins is shown in the lower panel Koong et al., 1994) . We chose polyoma mT-transformed cells because transformation does, in part, require Src activation (Guy et al., 1994) , and Ras-transformed cells because transformation does not require Src activation (Koong et al., 1994) . We observed that the phosphatase activity of Shp-2 immunoprecipitates from mT or Ras-transformed cells was 50 or 70% less, respectively, than that from untransformed cells (Figure 5b ). Immunoblot analysis showed that Shp-2 protein levels were equivalent in all cell lines (data not shown). Thus, the phosphatase activity of Shp-2 immunoprecipitates was decreased in cells transformed by proteins other than Src, and in transformed cells where Src was not activated. This result suggests that Shp-2 activity is downregulated in cells transformed by a variety of dierent proteins and the downregulation does not require activation of Src.
Tyrosine phosphorylation on Shp-2 does not correlate with Shp-2 activity in transformed cells
Early studies showed that tyrosine phosphorylation on Shp-2 correlates with enhancement of Shp-2 phosphatase activity (reviewed in Tonks and Neel, 1996; Vogel et al., 1993) . Thus, decreased tyrosine phosphorylation on Shp-2 might correlate with the decreased Shp-2 activity that we observed in transformed cells. Therefore, to investigate the mechanism by which Shp-2 activity is downregulated in transformed cells, we ®rst compared tyrosine phosphorylation on Shp-2 in transformed and untransformed cells. To do so, we immunoprecipitated Shp-2 from lysates of NIH3T3 cells or those overexpressing c-Src, v-Src, Y527F c-Src, mT or Ras and performed immunoblot analysis with an anti-phosphotyrosine antibody (Figure 6a , upper panel). We detected the highest levels of tyrosine phosphorylation on Shp-2 in Y527F c-Src (lane 3) and v-Src (lane 4) transformed cells. Lower levels of tyrosine phosphorylation on Shp-2 were detected in mT (lane 5) and Ras (lane 6) transformed cells, and the levels were not dierent from those detected in untransformed c-Src overexpressor cells (lane 2). In a control IgG immunoprecipitate (lane 7), we did not detect any tyrosine-phosphorylated proteins in the region of the gel where Shp-2 runs. When the ®lter was stripped of antibody to phosphotyrosine and incubated with Shp-2 antibody (Figure 6a , lower panel), equivalent levels of immunoprecipitated Shp-2 protein were detected in all lanes except that of the control IgG immunoprecipitate (lane 7). Overlaying the autoradiograms from the upper and lower panels con®rmed the location of Shp-2 on the antiphosphotyrosine blot (upper panel). Overall, levels of Shp-2 tyrosine phosphorylation did not correlate with levels of Shp-2 phosphatase activity (compare with Figure 5a and b). Thus, decreased Shp-2 activity in transformed cells does not result from decreased tyrosine phosphorylation on Shp-2. Interestingly, tyrosine-phosphorylated proteins ranging in size from 125 ± 150 kDa (bracket) co-immunoprecipitated with Shp-2 (Figure 6a upper panel) . One, of about 150 kDa was heavily phosphorylated on tyrosine in Y527F c-Src, v-Src and mT-transformed cells (lanes 3 ± 5). Another, of about 125 kDa was phosphorylated on tyrosine in Ras-transformed cells (lane 6).
Shp-2 preferentially associates with the membrane fraction of transformed cells Subcellular localization, and particularly membraneassociation of nonreceptor tyrosine kinases is known 1 and 2) , Y527F c-Src (lanes 3 and 4) or v-Src (lanes 5 and 6) were transfected with pcDNA3-Shp-2 and lysed 48 h later in hypotonic buer. Lysates were centrifuged at 100 000 g for 60 min and the supernatant (cystolic fraction; C) was decanted. The pellet was resuspended in 1% Triton X-100, centrifuged at 14 000 g for 30 min and the supernatant (membrane-soluble fraction; M) was decanted. Cytosolic fractions containing 10 mg of total cell protein, and the equivalent volume of membrane-soluble fractions, were subjected to immunoblot analysis with anti-Shp-2 antibody. Data are representative of 4 independent experiments to regulate their activity. It is possible that nonreceptor tyrosine phosphatases are regulated in a similar manner. Therefore, to further investigate the mechanisms by which Shp-2 activity is downregulated in transformed cells, we compared the subcellular localization of Shp-2 in transformed and untransformed cells. To do so, we prepared cytosolic and solubilized-membrane fractions of NIH3T3 cells overexpressing c-Src, Y527F c-Src or v-Src and subjected each fraction to immunoblot analysis with anti-Shp-2 (Figure 6b ). We observed relatively higher levels of Shp-2 protein in the solubilized-membrane fraction of the transformed cells than in the solubilized-membrane fraction of the untransformed cells (compare lanes 3 and 4 or 5 and 6 with lanes 1 and 2). Similarly, we observed relatively higher levels of Shp-2 protein in the solubilized-membrane fraction of cells transformed by Ras or mT than in those of untransformed cells (data not shown). Therefore, of the cell lines that we tested, transformed cells have relatively less Shp-2 activity and more membraneassociated Shp-2 protein than do untransformed cells. Our results suggest, but do not prove, that membraneassociation of Shp-2 is important for regulating Shp-2 activity.
Discussion
This study shows that Shp-2 activates Src, but not, that we can detect, by dephosphorylating Tyr 527. The ability of Shp-2 to regulate Src activity was shown in two ways. First, by overexpressing Shp-2 and demonstrating an increase in the speci®c activity of Src (Figure 1) and second, by inhibition of Shp-2 expression and demonstrating a decrease in the speci®c activity of Src (Figure 3) . Binding studies suggest a non-enzymatic mechanism by which Shp-2 activates Src. The phosphatase activity of Shp-2 immunoprecipitates is decreased in cells transformed by Src and other proteins, and Shp-2 preferentially associates with the membrane fraction of transformed cells.
Shp-2 is known to interact with a number of growth factor receptor tyrosine kinases and to have both positive and negative roles in their signaling pathways (reviewed in Tonks and Neel, 1996; Cossette et al., 1996) . Shp-2 also interacts with the nonreceptor tyrosine kinases Src, p210bcr-abl and JAK, and dephosphorylates Src and p210bcr-abl in vitro (Peng and Cartwright, 1993; Yin et al., 1997; Tauchi et al., 1994) . However, until now, studies have not been done to determine whether Shp-2 regulates the activities of these non-receptor tyrosine kinases in vitro. In this report, we show that Shp-2 activates the Src kinase in vitro (Figures 1 and 3) . We envision that Shp-2 regulates the in vivo activities of other tyrosine kinases besides Src.
Others have shown that tyrosine phosphatases can activate Src by dephosphorylating Tyr 527 (Zheng et al., 1992; den Hertog et al., 1993; Fang et al., 1994; Somani et al., 1997) . To the best of our knowledge, this is the ®rst report of a tyrosine phosphatase that activates Src by a mechanism other than this one. We ®nd that Shp-2 binds to the SH3 domain of Src ( Figure  4 ). Src family kinases are known to be activated by proteins that bind to their SH3 domains (Moare®, 1997) . Thus, it is tempting to suggest that Shp-2 activates Src by binding to its SH3 domain.
Shp-2 and related tyrosine phosphatases are known to bind to the SH3 domains of other proteins that they regulate. For example, after EGF stimulation, Shp-2 binds to the EGF receptor and the C-terminal SH3 domain of Grb2 and this leads to Ras activation (Wong and Johnson, 1996) . PEP, a non-receptor tyrosine phosphatase expressed in hemopoietic cells, binds to the SH3 domain of the Csk tyrosine kinase by a proline-rich region in the non-catalytic C-terminus of PEP (Cloutier and Veillette, 1996) . Thus, our results support those of others showing that Shp-2 can function as an adaptor protein by binding to SH3 (or SH2) domains of proteins, which in turn leads to oncogene activation Li et al., 1994; Wong and Johnson, 1996) . We envision that Shp-2 binds to SH3 domains of proteins in addition to Src and Grb2, thereby regulating other intracellular signaling pathways.
How could Shp-2 activate Src by binding to its SH3 domain? Although the speci®c mechanism is unknown, the recently identi®ed three-dimensional structure of Src kinases in the repressed state (Sicheri et al., 1997; Xu et al., 1997; Moare®, 1997) may provide clues. The SH3 domain interacts with the`back' of the catalytic domain and the linker segment connecting the SH2 domain to the catalytic domain. The linker forms a left-handed PP-II helix and interacts with the normal ligand-binding surface of the SH3 domain. Therefore, in the repressed state, the ligand-binding surface of the SH3 domain is engaged in intramolecular interactions. When the Srcrelated Hck kinase is mixed with the HIV Nef protein (which binds to the SH3 domain of Hck), the kinase activity of Hck increases dramatically (Moare®, 1997) , suggesting that ligands for the SH3 domain of Src kinases can displace the SH3 domain away from the linker and catalytic domain, thereby opening the molecule to the active state (Sicheri et al., 1997 ). Thus, it seems possible that Shp-2, like Nef, could stabilize the active state of Src kinases by binding to their SH3 domains. It will be important to determine whether Shp-2 interacts with other Src kinases via their SH3 domains. Our preliminary in vitro binding studies indicate that Shp-2 also interacts with the SH3 domain of the Src-related kinase, Yes (Walter AO and Cartwright CA, unpublished results).
Previously, we showed that Shp-2 can dephosphorylate Src at Tyr 527 in vitro (Peng and Cartwright, 1995) . We and others demonstrated that dephosphorylation of Tyr 527 in vivo activates c-Src to a transforming protein (Cartwright et al., 1987; Kmiecik and Shalloway, 1987; Piwnica-Worms et al., 1987; Reynolds et al., 1987) . Thus, we were surprised to ®nd that Shp-2 does not activate Src by this mechanism in vivo (Figures 1 and 2) . The most likely explanation for the discrepancy between our in vitro and in vivo results is the fact that phosphatases can promiscuously dephosphorylate proteins in vitro that are not physiologic substrates in vivo. The discrepancy demonstrates the importance of in vivo studies for determining the biologic relevance of phosphorylation events.
What is the mechanism by which Shp-2 phosphatase activity is downregulated in transformed cells? The mechanism does not appear to require activated Src kinases (present in v-Src, Y527F c-Src and mT transformed cells) because downregulation of Shp-2 activity is also seen in Ras-transformed cells ( Figure  5b) where Src is not activated (Koong et al., 1994) . Nor does the mechanism appear to involve decreased tyrosine phosphorylation on Shp-2, because tyrosine phosphorylation on Shp-2 is high in Src transformed cells (Figure 6a, lanes 3 and 4) where Shp-2 activity is low (Figure 5a ). While additional studies are needed to determine the speci®c mechanism by which Shp-2 activity is downregulated in transformed cells, data on the subcellular localization of Shp-2 in transformed cells may provide clues about a possible mechanism. We ®nd relatively more membrane-associated Shp-2 in transformed cells where Shp-2 activity is inhibited (compare Figures 6b and 5a) . Perhaps membrane localization brings Shp-2 in close proximity to an inhibitor.
The recently identi®ed three-dimensional structure of Shp-2 reveals a mechanism for catalytic inhibition; in the absence of a tyrosine-phosphorylated binding partner, the N-terminal SH2 domain of Shp-2 binds intramolecularly to the phosphatase domain and directly blocks its active site (Hof et al., 1998) . Our preliminary data show that Src's SH3 domain binds a proline-rich, highly-conserved motif in the catalytic domain of Shp-2, close to the region occupied by the Shp-2 N-terminal SH2 domain in the autoinhibited structure (Walter AO and Cartwright CA, unpublished data.). Thus, it is possible that in transformed cells, membrane-associated Shp-2-binding proteins, like Src, sterically block the catalytic cleft of Shp-2 and inhibit its activity. Additional studies are needed to test this hypothesis.
Recently, a family of transmembrane glycoproteins called signal-regulatory proteins (SIRPs) have been identi®ed (Fujioka et al., 1996; Kharitonenkov et al., 1997) . Upon mitogen stimulation, SIRP a proteins (molecular mass *120 kDa) become tyrosine phosphorylated by activated receptor tyrosine kinases, associate tightly with Shp-2 through Shp-2's SH2 domains, serve as a Shp-2 substrate and inhibit cellular responses induced by growth factors, oncogenes and insulin (Fujioka et al., 1996; Kharitonenkov et al., 1997) . Thus, the 125 ± 150 kDa tyrosinephosphorylated proteins that associate with Shp-2 in RIPA lysates of Src, mT and Ras transformed cells (Figure 6a , lanes 3 ± 6) may be members of the SIRP a family of regulatory proteins. The ®nding that the most heavily tyrosine phosphorylated of these proteins are present in cells that overexpress c-Src or contain activated Src kinases (Figure 6a , lanes 2 ± 5) suggests, but does not prove, that these proteins are substrates of the Src tyrosine kinase.
In summary, we have shown that the Shp-2 tyrosine phosphatase activates the Src tyrosine kinase via a non-enzymatic mechanism, and binds to Src's SH3 domain. These ®ndings indicate a novel mechanism of regulation of tyrosine kinases by tyrosine phosphatases. We suggest that membrane association of Shp-2 may be important for regulating Shp-2 activity. Understanding how tyrosine kinases and phosphatases regulate each other's activity will lead to a better understanding of their role in signaling pathways and cell growth control.
Materials and methods
Cell lines and antibodies
Cells were cultured in DMEM (Dulbecco's Modi®ed Eagle's Medium) supplemented with 10% bovine calf serum (Gibco, Paisley, UK). NIH3T3 cells transfected with pneoMLV chicken c-Src (3T3/c-Src cells; Cartwright et al., 1987) , or transformed with Y527F c-Src (Cartwright et al., 1987) , polyoma middle T (Cartwright et al., 1987) or Ha-Ras[V12] (Koong et al., 1994) , were maintained in G418 (200 mg/ml). Ha-Ras[V12]-transformed NIH3T3 cells were a gift of Amato Giaccia (Stanford University, Stanford, CA, USA), and v-Src transformed NIH3T3 cells were a gift of David Shalloway (Cornell University, Ithaca, NY, USA).
Src monoclonal antibody (MAb) 327, directed against the SH3 domain of Src (Lipsich et al., 1983) was used for Src immunoblot analyses and in vitro kinase assays. Polyclonal antibody Syp/SH-PTP2 directed against residues 2 ± 216 of Shp-2 (Upstate Biotechnology Incorporated (UBI), Lake Placid, NY, USA) was used for immunoblot analyses of Shp-2 expression in cells treated with sense or antisense oligonucleotides to shp-2 mRNA. Otherwise, Shp-2 MAb PTP1D directed against residues 1 ± 177 of Shp-2 (Transduction Laboratories, Lexington, KY, USA) was used for Shp-2 immunoprecipitations and immunoblot analyses. Polyclonal antibody C18-SH-PTP2, directed against residues 576 ± 593 of Shp-2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used for protein phosphatase assays and subcellular fractionation studies.
Site-directed mutagenesis and expression of mutant proteins
Site-directed mutagenesis of mouse Shp-2 in pBluescript SK (kindly provided by Tony Pawson, University of Toronto, Toronto, Canada; Feng et al., 1993) was performed using the Transformer Site-Directed Mutagenesis Kit according to the manufacturer's protocol (Clontech, Palo Alto, CA, USA). The C463S Shp-2 mutant was generated using the oligonucleotide primer 5'-CGTGGTTCACTCCAGCGCTGGG-3'. For selection against the unmutated plasmid the Switch Oligo BglII/ A¯III primer (Clontech) was used. The entire coding region of the mutant Shp-2 cDNA was sequenced to con®rm that the desired mutation was present and that no other mutations had been introduced. The EcoRI full-length wild-type or mutant Shp-2 DNA fragments were cloned into pcDNA3 for eukaryotic expression.
Transient expression assays
1610
6 cells were transfected with 10 mg of puri®ed plasmid DNA and 100 ml of Lipofectamine 2 according to the manufacturer's protocol (Gibco BRL, Gaithersburg, MD, USA). Cells were lysed 48 h after transfection.
Cell lysis, immunoprecipitations and immunoblot analysis
Unless otherwise stated, cells were lysed in RIPA buer (50 mM Tris pH 8.0, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.25% DOC and 0.1% SDS) containing 2 mM phenyl methyl sulfonyl¯uoride (PMSF), 10 mg/ml Aprotinin, 50 mM Leupeptin, 50 mM sodium¯uoride and 1 mM sodium vanadate. Lysate protein concentrations were measured by the BCA protein assay (Pierce, Rockford, IL, USA) (Cartwright et al., 1987; Park and Cartwright, 1995; Chang et al., 1998) . Lysates for immunoprecipitations (ip) were precleared with 30 ml of protein A/G sepharose slurry (1 : 1) (Pharmacia Biotech, Piscataway, NJ, USA) and 2 mg of rabbit or mouse IgG. Lysates were incubated with excess antibody for 1 ± 3 h at 48C (Chang et al., 1998) . Immune complexes were collected with 50 ml of protein A/G sepharose slurry and washed three times with 1 ml of lysis buer. Proteins were resolved by SDS-polyacrylamide gel electrophoresis (PAGE), transferred to nitrocellulose membranes, subjected to immunoblot analysis with the appropriate antibody (Cartwright et al., 1987; Park and Cartwright, 1995; Chang et al., 1998) and detected by enhanced chemiluminescence (ECL) according to the manufacturer's protocol (Amersham, Arlington Heights, IL, USA).
Immune complex kinase assays
MAb 327 or mouse IgG immunoprecipitates of precleared RIPA lysates containing 200 mg of total cellular protein were incubated for 10 min at 308C of buer containing 50 mM piperazine-N-N'-bis (2-ethanesulfonic acid) pH 7.0, 10 mM manganese chloride (MnCl 2 ), 10 mM dithiothreitol (DTT) and 30 mCi [g-32 P]ATP (4000 Ci mmol 71 , ICN, Costa Mesa, CA, USA) (Cartwright et al., 1987; Park and Cartwright, 1995; Chang et al., 1998) . Phosphorylated proteins were resolved by SDS ± PAGE and detected with Fuji medical RX ®lm and an intensifying screen at 7708C. [ 32 P] incorporation into Src was quanti®ed by scanning densitometry of autoradiograms (Cartwright et al., 1987; Park and Cartwright, 1995; Chang et al., 1998) .
Biosynthetic labeling and cyanogen-bromide (CNBr) cleavage of Src 1610 6 3T3/c-Src cells (plated on a 9 cm dish) were transfected with pcDNA3, pcDN3-Shp-2 or pcDNA3-C463S Shp-2, as described above. Twenty-four hours later, the transfected cells or 1610 6 3T3/Y527F c-Src cells (plated on a 9 cm dish) were washed three times in phosphate-free DMEM and incubated for 16 h at 378C in phosphate-free DMEM containing 5% dialyzed, phosphate-free calf serum and 1.5 mCi/ml of 32 P i (as H 3 32 PO 4 ; ICN) (Cartwright et al., 1987; Park and Cartwright, 1995) . Cells were lysed in RIPA buer and 32 P-labeled proteins were precipitated with MAb 327 and resolved by SDS ± PAGE. The gel was dried, exposed to ®lm and 32 P-labeled Src bands were excised from the gel. Excised gel pieces were rehydrated for 10 min in H 2 O, washed ®ve times in 10% methanol, lyophilized and incubated for 1 h at RT in 50 mg of CNBr (Sigma) per ml in 70% formic acid (Luo et al., 1991; Somani et al., 1997) . Gel pieces were washed ®ve times in H 2 O, dried and the CNBr-cleaved Src fragments were eluted by incubating and shaking for more than 6 h at 48C in 50 mM ammonium bicarbonate pH 8.5, 1% bmercaptoehanol, 0.1% SDS and 0.5 mM EDTA (Luo et al., 1991; Somani et al., 1997) . The gel pieces were collected by centrifugation and the supernatant containing the 32 Plabeled Src fragments was lyophilized, dissolved in SDS sample buer, boiled and separated on a 24% polyacrylamide gel (441 : 1 acrylamide-bisacrylamide (Luo et al., 1991; Somani et al., 1997) .
Oligonucleotide treatment of 3T3/c-Src cells
Sense S-oligonucleotides were synthesized to nucleotides 1 ± 18 of the shp-2 mRNA (5'-atgacatcgcggagatgG-3') and antisense S-oligonucleotides were synthesized to the complementary strand (5'-ccatctccgcgatgtcaT-3') (Operon Technologies, Alameda, CA, USA). 6610 5 3T3/c-Src cells were plated in 6-well tissue culture dishes. 24 h later cells were incubated in serum-free DMEM containing 2 mM of shp-2 sense or antisense S-oligo-nucleotides and 10 mg/ml Lipofectamine (Gibco ± BRL) (Dean et al., 1994) . After 4 h of incubation at 378C, the medium was exchanged for fresh DMEM containing 10% fetal bovine serum and 2 mM of shp-2 sense or antisense S-oligonucleotides, and the incubation was continued for an additional 36 h.
Expression and puri®cation of glutathione S-transferase (GST) fusion proteins
To generate GST-Src fusion constructs, regions of the wild-type (mouse) or DSH3 (chicken) Src cDNA were ampli®ed by polymerase chain reaction (PCR) using oligonucleotide primers that contained EcoRI or BamHI restriction sites to facilitate insertion of the ampli®ed fragments into EcoRI or EcoRI/BamHI linearized pGEX vector (Pharmacia Biotech):
Src DSH3: 5'-primer: 5'-CCGAATTCCATGGGGAGCAGCAAGACGC-3', 3'-primer: 5'-CCGAATTCCAGGCCTATAGGTTCTCTCC-3', Src SH2: 5'-primer: 5'-CGGGATCCGAGGAGTGGTACTTTGGC-3', 3'-primer: 5'-CGGAATTCCGCATCTTGGCCAATCC-3', Src SH3-SH2: 5'-primer: 5'-CGGGATCCCCCTGGCAGGTGGGGTGACC-3' pSGTsrcDSH3 plasmid (Erpel et al., 1995) was kindly provided by Sara Courtneidge (SUGEN, Redwood City, CA, USA). pGEX-Src-UD, pGEX-Src-SH3, pGEX-Src-UD/SH3 and pGEX-Src-UD/SH3/SH2 were gifts from Joosang Park. The entire coding region of all mutant cDNAs was sequenced to con®rm that the desired mutation was present and that no other mutations had been introduced.
pGEX-Src constructs were transformed into Escherichia coli strain DH5a. Overnight cultures were diluted 1 : 10 and grown at 378C until the OD 600 reached 1.0. Isopropyl-b-Dthiogalactoside was added to a ®nal concentration of 0.1 mM and the incubation was continued for 2 h at 308C (Chang et al., 1998) . The bacteria were harvested, resuspended in icecold phosphate-buered saline (PBS) and sonicated. Triton X-100 was added to a ®nal concentration of 1% and incubated for 30 min. After centrifugation at 12 000 g for 10 min, the supernatant was incubated with 50% slurry of Glutathione Sepharose 4B for 2 h at 48C with agitation (Chang et al., 1998) . Beads were washed three times with PBS and incubated with 10 mM reduced glutathione in 50 mM Tris/HCl (pH 8.0) for 10 min at room temperature (RT). The supernatant was dialyzed against Tris-buered saline overnight. Protein concentrations were measured using the BCA protein assay and the molecular mass of the GST-fusion proteins was con®rmed by SDS ± PAGE and staining with Coomassie Brilliant Blue G-250.
GST protein binding assays
NIH3T3 cells were transfected with pcDNA-3-Shp-2 and lysed 48 h later in NP-40 buer (50 mM Tris pH 8.0, 150 mM NaCl, 1 mM EDTA, 1% NP-40) containing 2 mM PMSF, 10 mg/ml Aprotinin, 50 mM Leupeptin, 50 mM sodium¯uoride and 1 mM sodium vanadate. Lysates were preincubated with 30 ml of glutathione sepharose slurry (Pharmacia Biotech) and 3 mg of puri®ed GST protein.
Lysate containing 200 mg of total cell protein was incubated for 4 h at 48C with approximately 0.5 mM of GST or GST-Src fusion protein which had been immobilized on glutathione sepharose beads for 30 min at 48C (Chang et al., 1998) . After extensive washing with NP-40 buer, the protein complexes were boiled in sample buer, and proteins were resolved by SDS ± PAGE, transferred to nitrocellulose membranes and subjected to immunoblot analysis with Shp-2 MAb PTP1D.
Protein phosphatase assays
Cells were lysed in RIPA buer lacking sodium vanadate. Polyclonal antibody C18-SH-PTP2 or rabbit IgG immunoprecipitates of lysate containing 500 mg of total cellular protein were washed three times in RIPA buer lacking sodium vanadate and once in phosphatase wash buer (50 mM HEPES pH 7.2, 150 mM NaCl, 1.5 mM MgCl 2 , 10% glycerol, 1% Triton X-100, 1 mM EGTA and 1 mM EDTA) (Guan et al., 1991) . Immunoprecipitates were incubated for 45 min at RT in 20 ml of reaction mixture (50 mM Imidazole pH 7.5, 10 mM DTT and 5 mM EDTA) containing 1.1610 5 c.p.m. of 32 P-labeled myelin basic protein (MBP) (Sigma) (Guan et al., 1991) . Trichloroacetic acid (TCA) (180 ml of a 20% solution) was added to stop the reaction and to precipitate MBP over 30 min at 48C. After centrifugation, 100 ml of supernatant was counted for released 32 P. MBP was phosphorylated on tyrosine by puri®ed human recombinant c-Src kinase (UBI) as follows: 50 mg MBP, 30 U Src kinase, 50 mM HEPES pH 7.2, 10 mM MnCl 2 , 1 mM DTT and 30 ml [g-32 P]ATP (in a ®nal volume of 60 ml) were incubated for 30 min at 308C (Guan et al., 1991) . TCA (40 ml of a 50% solution) was added to stop the reaction and to precipitate 32 P-labeled MBP over 30 min at 48C. After centrifugation, the pellet was washed three times with 20% TCA, dissolved in 100 ml H 2 O and 1 ml was counted.
Subcellular fractionation
Con¯uent plates (9-cm in diameter) of cells were washed three times with ice-cold PBS. Two ml of hypotonic lysis solution (20 mM HEPES NaOH pH 7.2, 5 mM sodium pyrophosphate, 5 mM EGTA, 1 mM MgCl 2 , 10 mg/ml Aprotinin, 50 mg/ml Leupeptin, 2 mM PMSF, 50 mM sodium¯uoride and 1 mM sodium vanadate) was added to each plate (Fujioka et al., 1996) . Ten minutes later, cells were scraped from the plates and homogenized with a Dounce homogenizer. The homogenate was centrifuged at 100 000 g for 60 min and the supernatant (cytosolic fraction) was decanted (Fujioka et al., 1996) . The pellet was suspended in 1 ml of membrane solubilization solution (20 mM Tris-HCl pH 7.6, 1% Triton X-100, 150 mM NaCl, 1 mM MgCl 2 , 10 mg/ml Aprotinin, 50 mg/ml Leupeptin, 2 mM PMSF, 50 mM sodium¯uoride and 1 mM sodium vanadate (Fujioka et al., 1996) . The suspension was centrifuged at 14 000 g for 30 min and the supernatant (solubilized membrane fraction) was decanted. Protein concentrations of the cytosolic fractions were determined by the BCA protein assay. For each cell line, proteins were immunoprecipitated with C18-SH-PTP2 antibody from a volume of cytosolic fraction containing 500 mg of protein, and from an equivalent volume of solubilized membrane fraction. All procedures were performed at 48C.
